Thought Leadership
 
Email Page
FDA Doubles Down in Its Updated Biologics Naming Guidance
March 19, 2019
Chad Landmon and Jonathan Knowles
The Center for Biosimilars

The Center for Biosimilars published, "FDA Doubles Down in Its Updated Biologics Naming Guidance," an article written by Axinn partner Chad Landmon and associate Jonathan Knowles.

Click here to access the article.